MikhailSKorenMD

PubMed

• 113 citations
  Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled anal...
  Evan A. Stein, Robert P. Giugliano, Michael J. Koren, Frederick J. Raal, Eli M. Roth, Robert M. Weiss, David R. Sullivan, Scott M. Wasserman, Ransi Somaratne, Jae B. K...> ;European Heart Journal. 2014 Sep 1
• 494 citations
  A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
  Dirk J. Blom, Tomas Hala, Michael A. Bolognese, Michael J. Lillestol, Phillip D. Toth, Lesley J. Burgess, Richard Ceska, Eli M. Roth, Michael J. Koren, Christie M. Bal...> ;The New England Journal of Medicine. 2014 May 7
• Anti-PCSK9 Monotherapy for Hypercholesterolemia - The MENDEL-2 Randomized, Controlled Phase 3 Clinical Trial of Evolocumab.
  Koren, M. J.,Lundqvist, P.,Bolognese, M.,Neutel, J. M.,Monsalvo, M. L.,Yang, J.,Kim, J. B.,Scott, R.,Wasserman, S. M.,Bays, H.> ;J. Am. Coll. Cardiol.. 2014 Apr 03
• Reduction in lipoprotein (a) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of over 1300 patients in 4 phase 2 trials.
  Raal, F. J.,Giugliano, R. P.,Sabatine, M. S.,Koren, M. J.,Langslet, G.,Bays, H.,Blom, D.,Eriksson, M.,Dent, R.,Wasserman, S. M.,Huang, F.,Xue, A.,Albizem, M.,Scott, R....> ;J. Am. Coll. Cardiol.. 2014 Feb 11
• Efficacy of combined local mechanical vibrations, continuous passive motion and thermotherapy in the management of osteoarthritis of the knee.
  Kitay, G. S., Koren, M. J., Helfet, D. L., Parides, M. K., Markenson, J. A.> ;Osteoarthr Cartil. 2009 Oct 01
• Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study.
  Smith, T. R., Glazer, R. D., Koren, M. J., Wernsing, M., Zhang, Y.> ;Int J Clin Pract. 2010 Sep
• Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
  Bella, J. N., Palmieri, V., Wachtell, K., Liu, J. E., Gerdts, E., Nieminen, M. S., Koren, M. J., Zabalgoitia, M., Wright, J. T., Dahlöf, B., Devereux, R. B.> ;J Hum Hypertens. 2004 Jun
• A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
  Hunninghake, D. B., McGovern, M. E., Koren, M., Brazg, R., Murdock, D., Weiss, S., Pearson, T.> ;Clin Cardiol. 2003 Mar
• Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris.
  Pepine, C. J., Cooper-DeHoff, R. M., Weiss, R. J., Koren, M., Bittar, N., Thadani, U., Minkwitz, M. C., Michelson, E. L., Hutchinson, H. G.> ;Am J Cardiol. 2003 Feb 1
• Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
  McKenney, J., Bays, H., Koren, M., Ballantyne, C. M., Paolini, J. F., Mitchel, Y., Betteridge, A., Kuznetsova, O., Sapre, A., Sisk, C. M., Maccubbin, D.> ;J Clin Lipidol. 2010 Mar 01
• Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treat...
  Feldman, T., Koren, M., Insull, W., McKenney, J., Schrott, H., Lewin, A., Shah, S., Sidisin, M., Cho, M., Kush, D., Mitchel, Y.> ;Am J Cardiol. 2004 Jun 15
• Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
  Koren, M. J., Davidson, M. H., Wilson, D. J., Fayyad, R. S., Zuckerman, A., Reed, D. P.> ;Am J Kidney Dis. 2009 May 01
• Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
  Straka, R. J., Mamdani, M., Damen, J., Kuntze, C. E., Liu, L. Z., Botteman, M. F., Koren, M. J.> ;Curr Med Res Opin. 2007 Jul
• Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
  Koren, M. J., Hunninghake, D. B.> ;J Am Coll Cardiol. 2004 Nov 2
• Join now to see all